Boston-based Verve is a rare example of a gene editing company targeting a disease that affects a large population, offering ...

Eli Lilly's stock price has over-corrected following a downgrade in its outlook following the adjustment for acquisition ...

Eli Lilly has struck a deal to buy Crispr gene-editing start-up Verve Therapeutics for up to $1.3bn, the latest acquisition ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

STORY: Eli Lilly said Monday it will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...